Dalvin LA, Zhang Q, Hamershock RA, et al. - In this investigation involving 1,131 patients, researchers created a nomogram for the anticipation of visual acuity outcome following plaque radiotherapy for uveal melanoma. A retrospective review of uveal melanoma treated for 2 years with plaque radiotherapy and prophylactic intravitreal injections of bevacizumab at 4-month intervals. Based on clinical risk factors or clinical and treatment risk factors, two nomograms for poor visual acuity outcome (Snellen < 20/200) have been developed. Subretinal fluid involving four quadrants, tumour thickness > 4 mm, presenting visual acuity ≤ 20/30, non-Caucasian race, tumour shape mushroom, bilobed, or multilobulated, and insulin-dependent diabetes were the most important clinical risk factors (points for nomogram) for poor visual acuity outcome. The most significant factors included presentation of visual acuity ≤ 20/30, tumour largest basal diameter > 11 mm, radiation dose rate to tumour base ≥ 164 cGy/hour, tumour thickness > 4 mm, insulin-dependent diabetes and abnormal foveolar status by optical coherence tomography at presentation. Following plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma, a nomogram using clinical or treatment risk factors can predict visual acuity outcome.